03.02.10
Asterand plc has launched GLP-compliant molecular pathology services supporting preclinical safety studies. The company’s first new service offering will be tissue cross reactivity testing for therapeutic antibodies in order to supply clients with critical data required by regulatory authorities for IND submissions.
Acceptance as a member of the UK GLP Compliance Monitoring Programme will also allow Asterand to expand its offering of GLP-compliant preclinical services to its pharmaceutical and biotech clients.
Dr. Tony Brown, Asterand's general manager, UK Operations, commented, “We are extremely pleased to add GLP-compliant tissue cross reactivity studies to our growing suite of PhaseZERO® services. These services will meet a critical need within a new market for Asterand. Our key customers are the world’s top 30 pharmaceutical companies, who increasingly look to source a broader range of services from external providers. This acceptance into the UK GLP Monitoring Compliance Programme allows us to broaden our service offering and provide more opportunities for our customers to develop 'one-stop shop' partnerships with Asterand.”
Acceptance as a member of the UK GLP Compliance Monitoring Programme will also allow Asterand to expand its offering of GLP-compliant preclinical services to its pharmaceutical and biotech clients.
Dr. Tony Brown, Asterand's general manager, UK Operations, commented, “We are extremely pleased to add GLP-compliant tissue cross reactivity studies to our growing suite of PhaseZERO® services. These services will meet a critical need within a new market for Asterand. Our key customers are the world’s top 30 pharmaceutical companies, who increasingly look to source a broader range of services from external providers. This acceptance into the UK GLP Monitoring Compliance Programme allows us to broaden our service offering and provide more opportunities for our customers to develop 'one-stop shop' partnerships with Asterand.”